SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex Therapeutics presented positive Phase 2 data for barzolvolimab…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed Mar 27, 2026 at 10:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 27, 2026 at 10:30 ET

Celldex Therapeutics presented positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), showing profound and sustained improvements in patient quality of life across all DLQI domains. The data support barzolvolimab’s potential as a first-in-class, disease-modifying therapy, with Phase 3 trials in CSU fully enrolled and top-line results expected in Q4 2026.

  • Barzolvolimab demonstrated up to 71% complete response (UAS7=0) in CSU patients after 52 weeks of treatment, with 41% maintaining complete response seven months after last dose.
  • 94% of CSU patients with well-controlled disease at Week 52 achieved DLQI 0/1, indicating no impact of disease on quality of life.
  • 76% of these patients maintained DLQI ≤5 (small to no impact) at Week 76, off-treatment, suggesting disease modification.
  • In ColdU and SD, barzolvolimab increased the rate of DLQI 0/1 by up to 3.1-fold (ColdU) and 4.0-fold (SD) vs placebo by Week 20.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access